GGrantIndex
← Leaderboards

Kathleen M Brasky

Southwest Foundation For Biomedical Res

Google Scholar ↗PubMed ↗ORCID ↗
$521,454
Attributed
$521,454
Total exposure
66
Grants
21
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $145.6K · FY2005–09
$200K$150K$100K$50K$0
'05
'06
'07
'08
'09

Funding mix

By agency

NIH$521,454 · 66

By mechanism

P51$521,454 · 66

Top collaborators

No co-investigators on record.

Most similar at Southwest Foundation For Biomedical Res

Same institution · by research overlap

Others in their field

Top investigators on “Primates”

Research focus

PrimatesAnimal ColonyResearch PersonnelUnited States National Institutes Of HealthComputer Retrieval Of Information On Scientific Projects DatabaseGrantSourceResourcesInstitutionFundingPharmacokineticsAntibody FormationPapioAntibodyResearch StudyHepatitis B VaccinesHepatitis B Surface AntigensMonoclonal AntibodyInfectionAnimalsBaboonsDoseDosageImmune Response

Grant awards (73)

MOLECULAR ONTOGENY OF ORAL MUCOSAL RESISTANCE TO SIV$13,938
P51 · FY2009 · RR · contact PI
EXPERIMENTAL INFECTION OF COMMON MARMOSET WITH EASTERN EQUINE ENCEPHALITIS VIRUS$15,702
P51 · FY2007 · RR · contact PI
TRX1 LEUCINE AND TRX1 PROLINE MABS GIVEN IV: PK, SAFETY, AND TOX$10,700
P51 · FY2007 · RR · contact PI
ANTIGEN COMPARABILITY STUDY OF HBSAG + 1018 ISS$6,046
P51 · FY2007 · RR · contact PI
HBV AND 1018 ISS VACCINE FORMULATION IN NEWBORN BABOONS$2,571
P51 · FY2007 · RR · contact PI
PREVNAR + C295 ISS VACCINE FORMULATION IN INFANT BABOONS$1,250
P51 · FY2007 · RR · contact PI
BABOON OPSONOKINE VACCINE STUDY$764
P51 · FY2007 · RR · contact PI
IMMUNOGENECITY OF NP-ISS COMBINED WITH INFLUENZA VIRUS VACCINE$23,009
P51 · FY2006 · RR · contact PI
EFFECTS OF IV ADMINISTERED AMG 108 IN CHIMPANZEES$11,930
P51 · FY2006 · RR · contact PI
DETERMINATION OF PROPHYLACTIC EFFICACY OF VARIOUS HEPATITS C VIRUS VACCINES$11,865
P51 · FY2006 · RR · contact PI
TESTING INFECTIVITY OF HCV ISOLATED FROM CELL CULTURE IN CHIMPANZEES$11,603
P51 · FY2006 · RR · contact PI
IMMUNOGENETHERAPY OF CHRONIC HCV CARRIER CHIMPANZEES$11,603
P51 · FY2006 · RR · contact PI
PHARMACOKINETIC, PHARMACODYNAMIC, SAFETY AND TOXICOLOGICAL COMPARABILITY STUDY$11,603
P51 · FY2006 · RR · contact PI
IN VITRO NEUTRALIZATION OF HCV WITH MONOCLONAL ANTIBODIES BEFORE ADMINISTRATION$11,603
P51 · FY2006 · RR · contact PI
BABOON OPSONOKINE VACCINE STUDY$11,603
P51 · FY2006 · RR · contact PI
PREVNAR + C295 ISS VACCINE FORMULATION IN INFANT BABOONS$11,603
P51 · FY2006 · RR · contact PI
HBV + C295 ISS-PMXB VACCINE IN BABOONS$11,603
P51 · FY2006 · RR · contact PI
EVALUATING THE IMMUNOGENICITY OF HBV-C295 ISS CONJUGATE IN COMBINATION WITH HBV$11,603
P51 · FY2006 · RR · contact PI
PHARMACOKINETICS AND IMMUNE RESPONSE STUDY WITH AN ANTI-CD3 MONOCLONAL ANTIBODY$5,179
P51 · FY2006 · RR · contact PI
TESTING HBV-KOREA SINGLE VIAL FORMULATION FOR IMMUNOGENICITY RESPONSE IN BABOONS$393
P51 · FY2006 · RR · contact PI
HBV AND 1018 ISS VACCINE FORMULATION IN NEWBORN BABOONS$393
P51 · FY2006 · RR · contact PI
IMMUNOGENECITY OF NP-ISS COMBINED WITH INFLUENZA VIRUS VACCINE$18,544
P51 · FY2005 · RR
EFFECTS OF IV ADMINISTERED AMG 108 IN CHIMPANZEES$9,610
P51 · FY2005 · RR
DETERMINATION OF PROPHYLACTIC EFFICACY OF VARIOUS HEPATITS C VIRUS VACCINES$9,558
P51 · FY2005 · RR
PHARMACOKINETICS AND IMMUNE RESPONSE STUDY WITH AN ANTI-CD3 MONOCLONAL ANTIBODY$4,156
P51 · FY2005 · RR
PHARMACOKINETICS OF TRX1 MONOCLONAL ANTIBODY BY SINGLE IV INJECTION$1,454
P51 · FY2005 · RR
TESTING THE IMMUNOGENICITY OF HBSAG COMBINED WITH NEW POLYMIXIN FORMULATIONS$831
P51 · FY2005 · RR
TESTING HBV-KOREA SINGLE VIAL FORMULATION FOR IMMUNOGENICITY RESPONSE IN BABOONS$312
P51 · FY2005 · RR
HBV AND 1018 ISS VACCINE FORMULATION IN NEWBORN BABOONS$312
P51 · FY2005 · RR
HEPATITIS C INFECTIVITY OF CHIMPANZEE PLASMA FROM PREVIOUS STUDY$6,687
P51 · FY2004 · RR
EVALUATION OF EXPERIMENTAL HIV VACCINES IN RHESUS MACAQUES II$5,684
P51 · FY2004 · RR
EVALUATION OF EXPERIMENTAL HIV VACCINES IN RHESUS MACAQUES$5,684
P51 · FY2004 · RR
INDUCTION OF TOLERANCE IN BABOONS WITH AN ANTI-CD4 ANTIBODY I$5,516
P51 · FY2004 · RR
IMMUNIZATION STUDY WITH MONOCLONAL ANTIBODY CNTO311 IN BABOONS$5,516
P51 · FY2004 · RR
PHARMACOKINETICS AND IMMUNE RESPONSE STUDY WITH AN ANTI-CD3 MONOCLONAL ANTIBODY$5,516
P51 · FY2004 · RR
IMMUNOGENICITY OF HBSAG COMBINED WITH NEW POLYMIXIN FORMULATIONS$5,516
P51 · FY2004 · RR
INDUCTION OF TOLERANCE IN BABOONS WITH HUMAN FACTOR VIII$5,516
P51 · FY2004 · RR
EFFECTS OF IV ADMINISTERED AMG 108 IN CHIMPANZEES$5,516
P51 · FY2004 · RR
PHARMACOKINETIC PROFILE OF A SINGLE AMG 108 DOSE IN CHIMPANZEES$5,516
P51 · FY2004 · RR
IMMUNIZATION AND PRODUCTION OF PRIMATE ANTIBODIES IN CYNOMOLGUS MACAQUES$5,516
P51 · FY2004 · RR
INFECTIVITY OF CULTURE FLUID FROM HCV RNA TRANSFECTED HUMAN LIVER CELLS$5,516
P51 · FY2004 · RR
PHARMACOKINETICS OF TRX1 MONOCLONAL ANTIBODY BY SINGLE IV INJECTION$5,516
P51 · FY2004 · RR
BABOON LYMPH NODE CELL ACTIVATION BY OLIGONUCLEOTIDES IN VITRO$5,516
P51 · FY2004 · RR
IMMUNOGENECITY OF NP-ISS COMBINED WITH INFLUENZA VIRUS VACCINE$5,516
P51 · FY2004 · RR
DOSE ESCALATION STUDY FOR THE ANTIBODY MT102 (ANTI CPCAMXANTI-CD3)$5,516
P51 · FY2004 · RR
DETERMINATION OF PROPHYLACTIC EFFICACY OF VARIOUS HEPATITS C VIRUS VACCINES$5,516
P51 · FY2004 · RR
SAFETY OF HBV-ANTIBODY IN HEP B CARRIER CHIMPANZEES$5,516
P51 · FY2004 · RR
STUDIES OF THE PHARMACOKINETICS OF A COMPOUND AFTER ORAL DOSING IN CHIMPANZEES$5,516
P51 · FY2004 · RR
INDUCTION OF TOLERANCE IN BABOONS WITH AN ANTI-CD4 ANTIBODY II$5,516
P51 · FY2004 · RR
EVALUATION OF EXPERIMENTAL HIV VACCINES IN RHESUS MACAQUES$49,020
P51 · FY2003 · RR
EVALUATION OF EXPERIMENTAL HIV VACCINES IN RHESUS MACAQUES II$49,020
P51 · FY2003 · RR
INDUCTION OF TOLERANCE IN BABOONS WITH AN ANTI-CD4 ANTIBODY I$3,193
P51 · FY2003 · RR
IMMUNOGENICITY OF HCV E1, E1, DNA WITH MICROPARTICLES IN RHESUS MACAQUES$3,193
P51 · FY2003 · RR
SAFETY OF HBV-ANTIBODY IN HEP B CARRIER CHIMPANZEES$3,193
P51 · FY2003 · RR
DOSE ESCALATION STUDY FOR THE ANTIBODY MT102 (ANTI CPCAMXANTI-CD3)$3,193
P51 · FY2003 · RR
DETERMINATION OF PROPHYLACTIC EFFICACY OF VARIOUS HEPATITS C VIRUS VACCINES$3,193
P51 · FY2003 · RR
STUDIES OF THE PHARMACOKINETICS OF A COMPOUND AFTER ORAL DOSING IN CHIMPANZEES$3,193
P51 · FY2003 · RR
DOSE-RANGE TOXICOLOGY STUDY OF ANTI-TISSUE FACTOR IN CHIMPANZEES$3,193
P51 · FY2003 · RR
BABOON LYMPH NODE CELL ACTIVATION BY OLIGONUCLEOTIDES IN VITRO$3,193
P51 · FY2003 · RR
PHARMACOKINETICS OF TRX1 MONOCLONAL ANTIBODY BY SINGLE IV INJECTION$3,193
P51 · FY2003 · RR
PHARMACOKINETICS AND IMMUNE RESPONSE STUDY WITH AN ANTI-CD3 MONOCLONAL ANTIBODY$3,193
P51 · FY2003 · RR
IMMUNOGENICITY OF HBSAG COMBINED WITH NEW POLYMIXIN FORMULATIONS$3,193
P51 · FY2003 · RR
INFECTIVITY OF CULTURE FLUID FROM HCV RNA TRANSFECTED HUMAN LIVER CELLS$3,193
P51 · FY2003 · RR
PILOT STUDY TO DETERMINE THE TOLERABILITY OF RAPAMYCIN IN BABOONS$3,193
P51 · FY2003 · RR
DOSE ESCALATION STUDY FOR THE BISPECIFIC SINGLE-CHAIN MONOCLONAL ANTIBODY MT103$3,193
P51 · FY2003 · RR
PROTECTIVE IMMUNE RESPONSE AGAINST HEPATITIS C VIRUS$3,193
P51 · FY2003 · RR
PHARMACOKINETIC PROFILE OF A SINGLE AMG 108 DOSE IN CHIMPANZEES$3,193
P51 · FY2003 · RR
EFFECTS OF IV ADMINISTERED AMG 108 IN CHIMPANZEES$3,193
P51 · FY2003 · RR
IMMUNIZATION AND PRODUCTION OF PRIMATE ANTIBODIES IN CYNOMOLGUS MACAQUES$3,193
P51 · FY2003 · RR
HEPATITIS C INFECTIVITY OF CHIMPANZEE PLASMA FROM PREVIOUS STUDY$3,193
P51 · FY2003 · RR
IMMUNIZATION STUDY WITH MONOCLONAL ANTIBODY CNTO311 IN BABOONS$3,193
P51 · FY2003 · RR
INDUCTION OF TOLERANCE IN BABOONS WITH HUMAN FACTOR VIII$3,193
P51 · FY2003 · RR
INDUCTION OF TOLERANCE IN BABOONS WITH AN ANTI-CD4 ANTIBODY II$3,193
P51 · FY2003 · RR